TP53 and cancer: Collectively, these findings across multiple cancer types strongly suggest that TP53/RB1 co‐alteration is a convergent molecular program driving lineage plasticity and transdifferentiation to small‐cell neuroendocrine carcinoma in epithelial tumors.